Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (658,963)	$ (669,705)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	98,578	134,773
Change in fair value of investments	53,413	79,225
Change in fair value of debt and liability instruments	76,045	27,672
Gain on deconsolidation of subsidiaries	(17,354)	(16,762)
Depreciation and amortization	11,426	7,753
Non-cash lease expense	3,316	4,194
Other	5,295	8,716
Changes in assets and liabilities, net of effects from acquisition and divestiture:
Other current assets	(26,279)	(30,219)
Accounts payable	10,142	6,774
Accrued expenses	(12,390)	1,447
Operating lease liabilities	(4,154)	(4,753)
Other	14,566	9,173
Net cash used in operating activities	(446,359)	(441,712)
Cash flows from investing activities:
Milestone payments	0	(140,136)
Purchase of property and equipment	(678)	(10,560)
Proceeds from sale of subsidiary interests	47,500	0
Cash decrease upon deconsolidation of subsidiaries	(83,679)	(3,615)
Other	511	0
Net cash used in investing activities	(36,346)	(154,311)
Cash flows from financing activities:
Proceeds from issuance of the Company's common shares, net of issuance costs paid	199,822	0
Proceeds from subsidiary debt financings, net of financing costs paid	0	159,899
Payment of subsidiary dividend	(6,000)	0
Repayment of debt by subsidiary	(14,471)	(14,685)
Payment of offering costs and loan origination costs	0	(2,250)
Payments on principal portion of finance lease obligations	(907)	0
Proceeds from exercise of the Company's and subsidiary stock options	42,142	0
Taxes paid related to net settlement of equity awards	(5,788)	(8,329)
Proceeds from issuance of the Company's common shares under employee stock purchase plan	587	0
Proceeds from exercise of the Company's warrants	5	0
Payment for redemptions of the Company's warrants	(41)	0
Net cash provided by financing activities	215,349	134,635
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(1,571)	0
Net change in cash, cash equivalents and restricted cash	(268,927)	(461,388)
Cash, cash equivalents and restricted cash at beginning of period	1,692,115	2,074,034
Cash, cash equivalents and restricted cash at end of period	1,423,188	1,612,646
Non-cash investing and financing activities:
Cashless exercise of the Company's warrants	83,258	0
Issuance of the Company's common shares and other consideration for an acquisition	0	9,694
Other	$ 33	$ 691